Mar 26 |
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
|
Mar 7 |
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
|
Mar 6 |
InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript
|
Mar 6 |
InspireMD GAAP EPS of -$0.16 beats by $0.03, revenue of $1.76M beats by $0.13M
|
Mar 6 |
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
Mar 5 |
InspireMD Q4 2023 Earnings Preview
|
Feb 28 |
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
|
Feb 12 |
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
|
Jan 31 |
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
|
Jan 23 |
We're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash Wisely
|